# Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06220318/  
OnCo record `nct06220318` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sintilimab in advanced solid tumours, run by Fujian Haixi Pharmaceuticals Co., Ltd., active and no longer recruiting.

## Summary

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06220318 by Fujian Haixi Pharmaceuticals Co., Ltd., with 155 participants enrolled, started 2023-07-19 and due to reach its primary completion in 2026-08-30. Interventions recorded: C019199 and Sintilimab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06220318
- Phase: 1/2
- Setting: A Phase I/II Clinical Study on the Safety, Tolerability and Preliminary Efficacy of C019199 in Combination With Sintilimab in Patients With Advanced Solid Tumors
- Sponsor: Fujian Haixi Pharmaceuticals Co., Ltd.
- Enrolled: 155

## Sources

- ClinicalTrials.gov NCT06220318: https://clinicaltrials.gov/study/NCT06220318

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Sintilimab](https://onco.cc/drugs/sintilimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06220318.json